MZT Holdings, Inc. (MZTH1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
330 NEVADA ST NEWTON, MA 02160

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

MZT Holdings, Inc., formerly Matritech, Inc., is a biotechnology company principally engaged in the development, manufacture, marketing, distribution and licensing of cancer diagnostic technologies and products. The products it has developed are based on its nuclear matrix protein (NMP) technology. Its first two products, the NMP221 Test Kit and NMP22 BladderChek Test, sales of which represent approximately 91% of the Company's total revenue for the year ended December 31, 2006, are designed to detect the presence of a specific protein marker in urine correlated with the presence of bladder cancer. The Company's sales of the NMP22 BladderChek Test are concentrated in the United States and Germany, where its own sales forces sell the NMP22 BladderChek Test directly to prescribing physicians. It has discovered other proteins associated with cervical, breast, prostate and colon cancer. In December 2007, Inverness Medical Innovations, Inc. acquired Matritech, Inc.

View SEC Filings from MZTH1 instead.

View recent insider trading info

MZT Holdings, Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding MZTH1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MZTH1

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2007-12-24 by MATRITECH INC

    • Events (8k)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MUSKET DAVID B

    • Director
    • 10% Owner
    		 0 2007-12-24 0

    JALBERT CRAIG R. PRESIDENT AND TREASURER

    • Officer
    		 0 2007-12-12 0

    THOMPSON T STEPHEN

    • Director
    		 10,000 2007-06-08 0

    ZADEL C WILLIAM

    • Director
    		 10,000 2007-06-08 0

    ROSENTHAL BOB

    • Director
    		 10,000 2007-06-08 0

    KURLAND JUDITH

    • Director
    		 10,000 2007-06-08 0

    FREDERICKS WALTER O

    • Director
    		 10,000 2007-06-08 0

    NILOFF JONATHAN M

    • Director
    		 10,000 2007-06-08 0

    LEHMAN BRUCE

    • Director
    		 10,000 2007-06-08 0

    CHUBB STEPHEN D CHAIRMAN AND CEO

    • Officer
    • Director
    		 150,000 2007-04-03 0

    CORBET DAVID L PRESIDENT AND COO

    • Officer
    • Director
    		 100,000 2007-04-03 0

    DOMURAD MELODIE R VP, CLINICAL AND REG. AFFAIRS

    • Officer
    		 40,000 2007-04-03 0

    QUIGLEY JOHN E VP, MARKETING

    • Officer
    		 15,000 2007-04-03 0

    SANDBERG RICHARD A VP, CFO, TREASURER, ASST. SEC.

    • Officer
    • Director
    		 25,000 2007-04-03 0

    RANDALL PATRICIA GENERAL COUNSEL, VP, CLO, SEC.

    • Officer
    		 50,000 2007-04-03 0

    MAIER FRANZ PRESIDENT, MATRITECH GMBH

    • Officer
    		 50,000 2007-04-03 0

    FAGAN GARY J VP, RESEARCH & DEV.

    • Officer
    		 27,673 2007-03-14 0

    KOLASINSKI DAVID VP, SALES

    • Officer
    		 43,528 2007-03-14 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments